In two patients (patients 3 and 5), new lesions were noted on 18F-PSMA-1007 PET/CT imaging after two cycles of RLT; in one case, new lymph node metastases with high PSMA-expression, but also pathological enlargement on CT were present, so that there were PD ratings using RECIST (new lesions), mPERCIST (new PSMA-avid lesions) and using SUVmax derived from the TTV (>30% increase of SUVmax). This evidence concerns the gene FOLH1 and metastatic malignant neoplasm in the lymph nodes.